ANXA5 and myocardial infarction: In the SDF‐1‐AnxA5‐treated group, the infarction size at 28 days after MI was significantly reduced compared to control group (12.4%±1.6% vs 37.8%±3.3%, P < .001, [infarction size as the ratio of infarct area/total ventricular area], Figure 5B).